Related Experiment Video
Updated: Jul 16, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Important therapeutic targets in chronic myelogenous leukemia
Hagop M Kantarjian1, Francis Giles, Alfonso Quintás-Cardama
1The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Summary
New tyrosine kinase inhibitors offer effective targeted strategies for chronic myelogenous leukemia (CML) patients resistant to imatinib therapy. These advanced treatments show high activity in clinical trials, improving outcomes for CML and Philadelphia chromosome-positive ALL.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR-ABL fusion gene.
- Imatinib mesylate targeted therapy has significantly improved survival in CML patients.
- Mechanisms of resistance to imatinib therapy are a major clinical challenge.
Purpose of the Study:
- To review the current understanding of CML biology and therapeutic strategies.
- To summarize imatinib resistance mechanisms and the efficacy of newer tyrosine kinase inhibitors (TKIs).
Main Methods:
- Literature review of CML pathophysiology, imatinib therapy, resistance mechanisms, and novel TKIs.
- Analysis of in vitro and clinical data for new TKIs like nilotinib and dasatinib.
Main Results:
- Imatinib targets BCR-ABL kinase activity, but resistance develops due to BCR-ABL mutations.
- Newer TKIs, nilotinib and dasatinib, are more potent and effective against imatinib-resistant mutants.
- Nilotinib and dasatinib demonstrate high activity in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Conclusions:
- Advances in understanding CML pathophysiology and resistance mechanisms have led to effective targeted therapies.
- Newer TKIs provide crucial treatment options for patients who develop resistance to imatinib.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...